SCHEMBL26980492

SCHEMBL26980492

Cc1cn(-c2nc(Nc3ccc(N4CCOCC4)cc3)ncc2F)c2ccc(N)cc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 2/20 0.56
▸ NPC1 O15118 1/20 0.52
▸ RAB9A P51151 1/20 0.52
▸ SMN1; SMN2 Q16637 1/20 0.52
▸ PLK4 O00444 2/20 0.50
▸ CDK2 P24941 2/20 0.48
▸ KCNH2 Q12809 1/20 0.48
▸ JAK2 O60674 4/20 0.47
▸ PDGFRB P09619 1/20 0.46
▸ PDGFRA P16234 1/20 0.46
▸ AURKA O14965 1/20 0.46
▸ AURKB Q96GD4 1/20 0.46
▸ PKMYT1 Q99640 1/20 0.45
▸ IGF1R P08069 3/20 0.45
▸ TP53 P04637 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ JAK3 P52333 2/20 0.45
▸ CCND3 P30281 2/20 0.44
▸ CCNK O75909 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26980153 0.90 CCNK (0.53) SYKCDK2JAK2PDGFRBPDGFRA
SCHEMBL26977050 0.86 SYK (0.49) SYKNPC1RAB9ASMN1; SMN2CDK2
SCHEMBL30671851 0.85 JAK2 (0.49) SYKNPC1RAB9ASMN1; SMN2CDK2
SCHEMBL29113559 0.85 JAK2 (0.49) SYKNPC1RAB9ASMN1; SMN2CDK2
SCHEMBL29113556 0.84 JAK2 (0.46) SYKNPC1RAB9ASMN1; SMN2CDK2
SCHEMBL26979838 0.84 BTK (0.56) SYKJAK2JAK3JAK1TYK2
SCHEMBL26979940 0.83 JAK2 (0.54) SYKPLK4CDK2JAK2PDGFRA
SCHEMBL27240931 0.76 BTK (0.58) JAK2JAK3JAK1TYK2
SCHEMBL30931315 0.76 BTK (0.58) JAK2JAK3JAK1TYK2
SCHEMBL26977136 0.76 CCND3 (0.49) SMN1; SMN2CDK2JAK2PDGFRBPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240190849-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE TYRA BIOSCIENCES, INC. 2024-06-13 — — US disclosed
EP-4297873-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE Tyra Biosciences, Inc. (US) 2024-01-03 — — EP disclosed
WO-2022182972-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE TYRA BIOSCIENCES, INC. (US) 2022-09-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240190849-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE DPYD, TYMP, TYMS SYK 2704/4885NPC1 3034/4885RAB9A 2014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback